Market Place
Sourcing Support
Avenue Therapeutics To Participate In Maxim Healthcare Summit
09 Oct 2024 //
GLOBENEWSWIRE
Avenue Therapeutics to Participate in Upcoming Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Reports Q2 2024 Results And Corporate Highlights
09 Aug 2024 //
GLOBENEWSWIRE
Avenue Therapeutics To Present At H.C. Wainwright 5th Annual Neuro Perspectives
20 Jun 2024 //
GLOBENEWSWIRE
Avenue`s AJ201 Muscle Atrophy Trial Completes Last Patient Visit
16 May 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Reports Q1 2024 Financials, Corporate Highlights
15 May 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Announces $4.4M Warrant Exercise
29 Apr 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Announces Reverse Stock Split
24 Apr 2024 //
GLOBENEWSWIRE
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024
25 Mar 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Reports Full Year 2023 Financial Results & Recent Highlights
18 Mar 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Reports Full Year 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
15 Mar 2024 //
GLOBENEWSWIRE
Avenue Therapeutics to Present BAER-101 Preclinical Data
11 Mar 2024 //
GLOBENEWSWIRE
Avenue Announces Publication Highlighting First-In-Class Data of BAER-101
22 Feb 2024 //
GLOBENEWSWIRE
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
11 Jan 2024 //
GLOBENEWSWIRE
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million
05 Jan 2024 //
GLOBENEWSWIRE
Avenue Reaches Final Agreement with FDA for Phase 3 Study for IV Tramadol
04 Jan 2024 //
GLOBENEWSWIRE
Avenue Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201
02 Jan 2024 //
GLOBENEWSWIRE
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
01 Dec 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
02 Nov 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
31 Oct 2023 //
GLOBENEWSWIRE
Avenue to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Avenue Announces Full Efficacy in a Model of Generalized Seizures for BAER-101
01 Aug 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Trial of AJ201
27 Jul 2023 //
GLOBENEWSWIRE
Avenue Announces Agreement with FDA on Phase 3 Safety Study for IV Tramadol
25 Jul 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
27 Apr 2023 //
GLOBENEWSWIRE
Avenue touts progress with FDA on embattled pain candidate after two CRLs
19 Apr 2023 //
ENDPTS
Avenue Announces Regulatory Update Based on Type C Meeting IV Tramadol
17 Apr 2023 //
GLOBENEWSWIRE
Avenue Reports Full Reports Full 2022 FYR and Recent Corporate Highlights
30 Mar 2023 //
GLOBENEWSWIRE
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics
10 Mar 2023 //
PR NEWSWIRE
Avenue Enters into a Transformational License Agreement with AnnJi
02 Mar 2023 //
GLOBENEWSWIRE
Avenue Announces Closing of $3.25 Million Registered Direct Placement
31 Jan 2023 //
GLOBENEWSWIRE
Avenue Announces $3.25 Million Registered Direct and Private Placement Priced
27 Jan 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Reports 3Q 2022 Financial Results & Recent Highlights
10 Nov 2022 //
GLOBENEWSWIRE
Avenue Therapeutics Completes the Acquisition of Baergic Bio
08 Nov 2022 //
BIOSPACE
Avenue Therapeutics Shares Jump 40% Following Stock Repurchase Move
14 Oct 2022 //
FIRSTWORLDPHARMA
Avenue Therapeutics Announces Closing of $12 M Underwritten PO
11 Oct 2022 //
GLOBENEWSWIRE
Avenue Therapeutics (ATXI) Stock: Why It Fell Over 50% Today
07 Oct 2022 //
PULSE2
Avenue Therapeutics Announces Pricing of $12 MUnderwritten Public Offering
06 Oct 2022 //
GLOBENEWSWIRE
Why Avenue Therapeutics Stock’s 107% Moonshot is Probably an Illusion
27 Sep 2022 //
NASDAQ
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update
22 Sep 2022 //
GLOBENEWSWIRE
Avenue Tx Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
15 Feb 2022 //
GLOBENEWSWIRE
Avenue Therapeutics IV pain therapy to go under FDA review amid safety concerns
11 Feb 2022 //
SEEKINGALPHA
Avenue Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA
29 Nov 2021 //
GLOBENEWSWIRE
Avenue Announces Exercise and Closing of Underwriter’s Over-Allotment
17 Nov 2021 //
GLOBENEWSWIRE
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
12 Nov 2021 //
GLOBENEWSWIRE
Avenue Therapeutics Prices $2.6 M Underwritten Public Offering of Common Stock
09 Nov 2021 //
GLOBENEWSWIRE
Avenue Receives Interim Response to its Formal Dispute Resolution Request
25 Oct 2021 //
GLOBENEWSWIRE
Avenue Therapeutics Appeal Seeking Approval for Pain Drug Denied by FDA
27 Aug 2021 //
MORNING STAR
U.S. FDA declines to approve Avenue’s IV formulation of painkiller
14 Jun 2021 //
REUTERS
Avenue`s IV tramadol pain drug gets another negative FDA response
14 Jun 2021 //
MARKET WATCH
Avenue Announces that the FDA is Still Reviewing NDA Resubmission IV Tramadol
13 Apr 2021 //
GLOBENEWSWIRE
Avenue Announces Publication of Real-World Data on Nonmedical Use of Tramadol
18 Dec 2020 //
GLOBENEWSWIRE
Avenue Announces Publication of Real-World Data on Nonmedical Use of Tramadol
18 Dec 2020 //
GLOBENEWSWIRE
Avenue Therapeutics receives Complete Response Letter from USFDA for IV tramadol
12 Oct 2020 //
BUSINESS-STANDARD
FDA sends small biotech and its reformulated pain med, triggering a collapse
12 Oct 2020 //
ENDPTS
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
21 Jul 2020 //
GLOBENEWSWIRE
